EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

07 2 2025 07:06:54 提供 Nasdaq GlobeNewswire

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

16 1 2025 07:00:03 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

14 1 2025 06:30:34 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

13 1 2025 08:27:39 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

08 1 2025 06:45:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

08 1 2025 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

16 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

06 11 2024 15:49:03 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

06 11 2024 15:05:01 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

04 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

23 10 2024 06:30:55 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

08 10 2024 16:32:28 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

02 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

26 9 2024 07:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

25 9 2024 06:07:16 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

13 9 2024 05:45:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

12 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

03 9 2024 06:08:45 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

30 8 2024 07:16:09 提供 Nasdaq GlobeNewswire

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

29 8 2024 17:53:02 提供 Nasdaq GlobeNewswire